Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Capnia Closes Second Tranche of Private Placement of Convertible Preferred Stock
-
Maxim Group Positive on Anavex (AVXL) Dose Response Curve
-
Maxim Group Upgrades Momenta Pharmaceuticals (MNTA) to Hold
-
Maxim Group Downgrades AO Smith (AOS) to Hold
-
OTG EXP, Inc. Files Registration Statement for Initial Public Offering of Common Stock
-
Out of flavor: Wall Street slashes targets on Chipotle
-
Streetinsider.com's Hot Lunchtime Reads 1/7: (TSLA) (GSI) (NFLX) (ADTN)
-
Maxim Group Reiterates $5 Price Target on Mast Therapeutics (MSTX)
-
Galena Biopharma (GALE) Prices 19.8M Common Stock and Warrant Offering at $1.10/Unit
-
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants
-
Maxim Group Downgrades Caladrius Biosciences (CLBS) to Hold
-
Epizyme (EPZM) Prices 13.33M Common Offering at $9/Share
-
Epizyme Announces Pricing of Public Offering of Common Stock
-
Apple shares drop below $100 for first time since August
-
The Alliance for Regenerative Medicine Announces 2016 Regen Med and Advanced Therapies State of the Industry Briefing
-
Chipotle hit with U.S. subpoena over California norovirus outbreak
-
Inovio (INO) PT Lowered to $14 at Maxim Group; 'Buy' Maintained
-
bluebird bio (BLUE) PT Cut to $105 at Maxim Group; 'Buy' Maintained
-
The Joint Corp. Announces Exercise of Over-Allotment Option
-
Gilead (GILD) Bullish Stance Reiterated at Maxim Group Following Priority Review for Sofosbuvir in Chronic HCV
-
Benitec BioPharma (BNTC) PT Lowered to $14 at Maxim Group
-
Streetinsider.com's Hot Lunchtime Reads 12/31: (EGY) (SWHC) (AAPL) (VRX)
-
IntelliPharmaCeutics (IPCI) PT Lowered to $6 at Maxim Group
-
Anavex Life Sciences (AVXL) Losses Mount Amid SEC Subpoena, Investigation
-
Mesoblast Limited (MESO) PT More Than Doubled at Maxim Group
-
ContraFect (CFRX) PT Cut to $9 at Maxim Group; 'Buy' Maintained
-
Maxim Group Doesn't See Anything Nefarious at Anavex (AVXL)
-
Blue Sphere Completes Financing
-
Blue Sphere Completes Financing
-
Streetinsider.com's Hot Lunchtime Reads 12/23: (STEM) (ADMS) (LL) (CHK)
-
StemCells (STEM) PT Cut to $3 at Maxim Group
-
Maxim Group Reiterates Sell on Momenta (MNTA)
-
Athersys (ATHX) PT Cut to $5 at Maxim Group; 'Buy' Maintained
-
Caladrius Biosciences (CLBS) PT Cut to $4 at Maxim Group; 'Buy' Maintained
-
Galena Biopharma (GALE) PT Cut to $4 at Maxim Group; 'Buy' Maintained
-
Pluristem Therapeutics (PSTI) PT Cut to $3 at Maxim Group; 'Buy' Maintained
-
Maxim Group Downgrades Cesca Therapeutics (KOOL) to Hold
-
Brainstorm Cell Therapeutics (BCLI) PT Cut to $5 at Maxim Group; 'Buy' Maintained
-
Capnia (CAPN) PT Trimmed to $3 at Maxim Group; 'Buy' Maintained after Granted Ophan Designation
-
Cytori Therapeutics (CYTX) Enters Agreements with Series A-1, A-2 Warrantholders; Updates on Cash Burn
-
Cytori Amends Corporate Warrant Agreements Simplifying Capital Structure and Updates on 2015 Operating Cash Burn Guidance
-
Maxim Group Starts Abeona Therapeutics (ABEO) at Buy
-
Maxim Group Starts Tristate Capital Holdings (TSC) at Buy
-
Maxim Group Starts ConnectOne Bankcorp (CNOB) at Buy
-
Maxim Group Starts Popeyes Louisiana Kitchen (PLKI) at Buy
-
Aeterna Zentaris (AEZS) Closes Common, Warrants Offering for Net Proceeds of ~$15M
-
Aeterna Zentaris Announces Closing of US$16.65 Million Public Offering of Common Shares and Warrants
-
X4 Pharmaceuticals Unveils Development Strategy for CXCR4 Inhibitor Pipeline in Cancer Supported by $37.5 million Series A Financing
-
Gladstone Land (LAND) Prices Reduced 900k Common Offering at $8.82/Share
-
Gladstone Land Corporation Announces Pricing of Common Stock Offering

